{
  "docId": "019de071-f579-76ad-bea5-b34da2c83a75",
  "docSlug": "563487226462eb4ab63630eb9b74a5cf",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 42 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 42,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "comparison_table",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 42,
  "notes": "Clinical trial safety data comparing combination therapy vs monotherapy vs standard of care.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-f579-76ad-bea5-b34da2c83a75/23",
  "deckHref": "/decks/019de071-f579-76ad-bea5-b34da2c83a75",
  "deckJsonHref": "/decks/019de071-f579-76ad-bea5-b34da2c83a75.json",
  "deckAnchorHref": "/decks/019de071-f579-76ad-bea5-b34da2c83a75#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.04,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "Includes AEs with onset or increase in severity on or after the date of the first dose through 90 days following the last dose. *Treatment-related as assessed by investigator. †Nervous system disorder (n=1), acute respiratory distress syndrome (n=1), hepatitis (n=1), immune-mediated hepatitis (n=2), pneumonitis (n=1), hepatic failure (n=1), myasthenia gravis (n=1). ‡Hematuria (n=1), cerebral hematoma (n=1), hepatic failure (n=1). AE, adverse event; SMQ, Standardized MedDRA Query; T300+D, tremelimumab 300 mg x 1 dose + durvalumab 1500 mg Q4W; TRAE, treatment-related adverse event.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6dd69ecf-a88d-477d-8148-e589af892e6a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.228
      },
      "kind": "table",
      "text": "Comparison of AE and TRAE metrics across T300+D, Durvalumab, and Sorafenib arms.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0c020249-8ffb-4b50-8da6-78567de4509f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.38,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Safety and tolerability",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "47fe00e7-c030-4fbc-abcc-9ae14b1b2d93",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Comparison frame",
      "slug": "comparison-frame",
      "agent": null,
      "layer": "slide",
      "matchId": "5d920129-4541-4d48-b7e6-cf4b80ab6900",
      "evidence": "The comparison of AE and TRAE metrics across different arms serves as a comparison frame.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 25,
      "from": 9,
      "beatId": "5bf1753c-e4a0-4e18-b568-73af9c0043f2",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The deck presents data and results for Imfinzi TOPAZ-1 and HIMALAYA, demonstrating their effectiveness",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}